Product Details
| Product Name:
Gemigliptin |
CAS No.:
911637-19-9 |
| Purity:
99.72% |
Supply Ability:
10g |
| Release date:
2026/07/27 |
Product Introduction
Bioactivity
| Name | Gemigliptin |
| Description | Gemigliptin (LC15-0444) is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor(KD : 7.25 nM.) |
| Cell Research | Using immunohistochemical and Western blot analysis, Quantitated components of the NLRP3 inflammasome in kidneys with and without gemigliptin treatment, and in vitro in human kidney tubular epithelial human renal proximal tubule cells (HK-2) cells, further analyzed the effect of gemigliptin on transforming growth factor-β (TGF-β)-stimulated production of profibrotic proteins[2]. |
| In vitro | Gemigliptin attenuated vascular calcification and osteogenic trans-differentiation in vascular smooth muscle cells via multiple steps including downregulation of PiT-1 expression and suppression of reactive oxygen species generation, phospho-PI3K/AKT, and the Wnt signaling pathway[1].Gemigliptin treatment attenuated phosphorylated nuclear factor-κB levels, which had been increased in the UUO kidney as well as in TGF-β-treated cultured renal cells[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (8.17 mM), Sonication is recommended.
DMSO : 122.5 mg/mL (250.33 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Gemigliptin | DPP-4 | DPP4 | DPP | Dipeptidyl Peptidase |
| Inhibitors Related | Trelagliptin | Trelagliptin succinate | Sitagliptin | Saxagliptin hydrate | Teneligliptin hydrobromide | Sitagliptin phosphate monohydrate | Nateglinide | Anagliptin | Linagliptin | Vildagliptin | Sitagliptin phosphate | Imigliptin |
| Related Compound Libraries | Highly Selective Inhibitor Library | Glycometabolism Compound Library | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Hematonosis Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Metabolism Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Senova Technology Co. Ltd.
|
2022-09-01 |
United States